Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia.
In 20 women with menorrhagia (greater than 80 ml blood loss per menstrual period) a levonorgestrel-releasing intrauterine device (Lng-IUCD) was inserted. Menstrual blood loss (MBL) was measured in two consecutive cycles before the device was inserted and after 3, 6 and 12 months of use. MBL was significantly reduced after 3 months (86%) and after 12 months the reduction was 97%. There was a significant increase (P less than 0.001) in serum ferritin during the first year of Lng-IUCD use. The Lng-IUCD seems to be an important alternative to oral medication and to hysterectomy in the treatment of menorrhagia.
Andersson
J K
JK
Department of Obstetrics and Gynaecology, East Hospital, University of Göteborg, Sweden.
Rybo
G
G
D000328:Adult; D003258:Consumer Behavior; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D005260:Female; D005293:Ferritins / Q000097:blood; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel; D008595:Menorrhagia / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage*; D011379:Prognosis; D011788:Quality of Life; D013997:Time Factors
D003271:Contraceptive Agents, Female; D006454:Hemoglobins; D009644:Norgestrel; D016912:Levonorgestrel; D005293:Ferritins